```html

Quinine Overdose – Cinchonism

What is Quinine Overdose – Cinchonism?

Quinine is an alkaloid derived from the bark of the cinchona tree. Historically it was the main treatment for malaria, and today it is still used in prescription tablets for nocturnal leg cramps and in some over‑the‑counter (OTC) “tonic water” beverages (which contain up to 83 mg per 12‑oz serving). When a person ingests more quinine than the body can safely metabolize, a collection of toxic effects known as cinchonism can develop.

Cinchonism is not a disease in itself; rather, it is a syndrome of symptoms that result from quinine’s direct impact on the central nervous system, heart, kidneys, and auditory‑vestibular pathways. Mild forms may present as a transient metallic taste, while severe toxicity can lead to life‑threatening arrhythmias, severe thrombocytopenia, and irreversible hearing loss.

Because quinine toxicity is dose‑dependent, the same person may tolerate a therapeutic dose (e.g., 200 mg once daily for leg cramps) but develop cinchonism after a single accidental overdose, prolonged self‑medication, or consumption of large volumes of tonic water.

Common Causes

• **Prescription misuse** – Taking higher-than‑prescribed doses of quinine tablets for nocturnal leg cramps.
• **Self‑treatment of malaria** – Using quinine without medical supervision, especially in travelers returning from endemic regions.
• **Excessive tonic water consumption** – Drinking >1 L of tonic water daily can lead to cumulative quinine intake >300 mg.
• **Accidental overdose** – Confusing quinine tablets with other medications or taking a double dose.
• **Combination with other QT‑prolonging drugs** – e.g., certain antibiotics, antipsychotics, or antiarrhythmics that amplify cardiac risk.
• **Renal impairment** – Reduced clearance of quinine, causing accumulation even at standard doses.
• **Herbal or dietary supplements** – Some “natural” malaria remedies contain quinine or related alkaloids.
• **Intentional ingestion** – Rare cases of suicide attempts involving quinine tablets.
• **Medication errors in hospitals** – Incorrect dosing in IV quinine infusions for severe malaria.
• **Chronic use for “muscle cramping”** – Long‑term over‑use can gradually increase serum levels.

Associated Symptoms

The symptom pattern of cinchonism can be grouped into four main systems:

Neurologic & Sensory

• Metallic or bitter taste (often the first clue)
• Headache, dizziness, and light‑headedness
• Visual disturbances (blurred vision, photophobia)
• Tinnitus, ringing in the ears, or hearing loss (sometimes irreversible)
• Peripheral neuropathy – tingling, numbness, or burning sensation in hands/feet

Cardiovascular

• Palpitations
• Chest discomfort or tightness
• Arrhythmias, especially torsades de pointes due to QT prolongation

Hematologic & Renal

• Thrombocytopenia (low platelet count) → easy bruising, petechiae
• Hemolytic anemia in susceptible individuals
• Acute kidney injury due to direct tubular toxicity

Gastrointestinal

• Nausea, vomiting, abdominal cramps
• Diarrhea (less common)

Symptoms usually appear within 30 minutes to a few hours after a large dose, but delayed cardiotoxic effects can emerge up to 24 hours later.

When to See a Doctor

Any of the following warrants prompt medical evaluation:

• Persistent metallic taste lasting more than a few hours.
• New or worsening tinnitus, hearing loss, or vertigo.
• Chest pain, palpitations, or irregular heartbeat.
• Unexplained bruising, petechiae, or bleeding gums (possible thrombocytopenia).
• Severe nausea/vomiting that prevents oral intake.
• Sudden drop in urine output or flank pain (suggesting kidney injury).
• Any sign of an allergic‑type reaction – rash, swelling, difficulty breathing.

Even if symptoms seem mild, informing a health‑care professional is important because laboratory testing may reveal dangerous electrolyte or blood‑count abnormalities that are not yet clinically apparent.

Diagnosis

Diagnosis of cinchonism is primarily clinical, supported by a focused history and targeted investigations:

History & Physical Exam

• Exact amount of quinine ingested, timing, and formulation (tablet, tonic water, IV).
• Concomitant medications, especially other QT‑prolonging agents.
• Renal or hepatic disease history.
• Physical signs: pallor, bruises, tachycardia, abnormal heart sounds, neurologic deficits.

Laboratory Tests

• Serum quinine level – rarely done but helpful in severe cases.
• Complete blood count (CBC) – look for thrombocytopenia or anemia.
• Comprehensive metabolic panel – especially potassium, magnesium, calcium, and renal function (creatinine, BUN).
• Liver function tests – quinine is metabolized hepatically.

Cardiac Evaluation

• 12‑lead electrocardiogram (ECG) – assess QT interval, presence of arrhythmias.
• Continuous cardiac monitoring if QTc > 500 ms or symptomatic.

Audiologic Assessment

• Pure‑tone audiometry or bedside tuning‑fork tests if hearing loss is reported.

Imaging (rare)

• Renal ultrasound if acute kidney injury is suspected and the cause is unclear.

Treatment Options

Management focuses on preventing further absorption, supporting organ systems, and closely monitoring cardiac rhythm.

Immediate Measures

• Deactivate further intake: Stop any quinine‑containing products.
• Activated charcoal: If the patient presents within 1–2 hours of ingestion and has a protected airway, a single dose (1 g/kg) can reduce quinine absorption.
• Gastric lavage: Reserved for massive ingestions within 30 minutes and only in a controlled setting.

Supportive Care

• IV fluids to maintain renal perfusion and correct electrolyte disturbances (especially potassium and magnesium).
• Anti‑emetics (e.g., ondansetron) for nausea/vomiting.
• Analgesics for headache (avoid NSAIDs if platelet count is low).

Cardiac Management

• Continuous ECG monitoring.
• If QTc > 500 ms or torsades occurs, give IV magnesium sulfate 2 g over 15 minutes.
• Temporary pacing may be required for refractory bradyarrhythmias.
• Discontinue other QT‑prolonging drugs.

Hematologic & Renal Support

• Platelet transfusion if severe thrombocytopenia (<10,000/µL) with active bleeding.
• Consider fresh‑frozen plasma for coagulopathy.
• Dialysis is rarely needed but may be employed in severe renal failure or if quinine levels remain high despite supportive care.

Symptom‑Specific Interventions

• Referral to an otolaryngologist for persistent tinnitus or hearing loss.
• Physical therapy for neuropathic pain.

Disposition

• Mild cases with normal labs and ECG can be observed for 6–12 hours and discharged with education.
• Moderate‑to‑severe cases require admission to an intensive care or step‑down unit for monitoring.

Prevention Tips

• Use quinine only under a physician’s prescription; follow the exact dosage.
• Read medication labels carefully; do not double‑dose “as needed.”
• If you enjoy tonic water, limit intake to ≤ 250 mL (≈8 oz) per day.
• Inform your doctor about all OTC drinks, supplements, and herbal products.
• Patients with kidney or liver disease should avoid quinine unless absolutely necessary.
• Store quinine tablets out of reach of children and pets.
• When traveling to malaria‑endemic regions, use WHO‑recommended prophylaxis (e.g., atovaquone‑proguanil) instead of self‑medicating with quinine.
• Ask pharmacists to double‑check prescriptions for potential drug interactions that could raise quinine levels.

Emergency Warning Signs

Key Take‑aways

Quinine overdose—cinchonism—is a dose‑dependent toxicity that can affect the heart, blood cells, kidneys, and auditory system. While mild cases resolve with cessation of the drug and supportive care, severe toxicity can be life‑threatening. Prompt recognition, early cardiac monitoring, and correction of electrolyte disturbances are the cornerstones of treatment. Preventive measures, including careful dosing, awareness of hidden quinine sources (like tonic water), and communication with health‑care providers, dramatically reduce the risk of overdose.

References:

• Mayo Clinic. “Quinine side effects.” https://www.mayoclinic.org
• U.S. Food & Drug Administration. “Quinine-containing Products: FDA Warning.” 2022.
• American Heart Association. “Drug-Induced QT Prolongation.” 2023.
• Cleveland Clinic. “Cinchonism (Quinine Toxicity).” 2024.
• World Health Organization. “Guidelines for the Treatment of Malaria.” 2021.
• National Center for Biotechnology Information. “Quinine Toxicity: A Review of Clinical Manifestations.” J Clin Pharmacol. 2020;60(5):669‑680.

```